Sandoz Group (OTCMKTS:SDZNY - Get Free Report) was upgraded by Barclays from a "hold" rating to a "strong-buy" rating in a research report issued on Tuesday,Zacks.com reports.
A number of other analysts also recently issued reports on SDZNY. Jefferies Financial Group raised Sandoz Group from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 12th. The Goldman Sachs Group raised Sandoz Group to a "strong-buy" rating in a research note on Wednesday, April 1st. Finally, Royal Bank Of Canada downgraded Sandoz Group from a "moderate buy" rating to a "hold" rating in a research note on Monday, March 23rd. Three research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Sandoz Group currently has a consensus rating of "Strong Buy".
View Our Latest Report on SDZNY
Sandoz Group Price Performance
Shares of SDZNY opened at $84.29 on Tuesday. Sandoz Group has a 52-week low of $44.02 and a 52-week high of $94.15. The stock has a fifty day simple moving average of $81.61 and a two-hundred day simple moving average of $76.13. The company has a quick ratio of 0.77, a current ratio of 1.18 and a debt-to-equity ratio of 0.53.
Sandoz Group Company Profile
(
Get Free Report)
Sandoz Group OTCMKTS: SDZNY is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.
The company's product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sandoz Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sandoz Group wasn't on the list.
While Sandoz Group currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
